PTO/SB/08 (08-00

PTO/SB/08 (08-00 Approved for use through 10/31/2002. OMB 0651-003

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control

Substitute for form 1449B/PTO Complete if Known NFORMATION DISCLOSURE **Application Number** 09/972,245 TATEMENT BY APPLICANT **Filing Date** 10/09/2001 Natarajan SETHURAMAN First Named Inventor te Submitted: January 31, 2003 Group Art Unit 1645 **Examiner Name** use as many sheeta as necessary) Not yet assigned Attorney Docket Number 078728-0104

U.S. PATENT DOCUMENTS								
Examiner Initials*	Cite No.1	U.S. Patent Number	Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
715	A1	5,880,255		DELGADO et al.	03/09/1999	RECEIVEL		
						FEB 0 3 2003		
						TECH CENTER 1600/		

				FC	DREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No. ¹	For Office ³	eign Patent D Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		_						
								ļ
							777	╂
								

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cîte No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ ⁶
R	A2	HOLCENBERG et al. "Biologic and Physical Properties of Succinylated and Glycosylated Acinetobacter Glutaminase-Asparaginase"; The Journal of Biological Chemistry, Vol. 250, No. 11, 6/75, pp. 4165-4170.	
RS	A3	FUERTGES et al. "The Clinical Efficacy of Poly(Ethylene Glycol)-Modified Proteins", Journal of Controlled Release, 12 (1990) January , No. 1/3, Amsterdam, NL, pp. 139-148.	
R	A4	KAFKEWITZ et al., "Enzyme-induced asparagine and glutamine depletion and immune system function", The American Journal of Clinical Nutrition 37: June 1983, pp. 1025-1030	

Examiner Signature	le	Date Considered	8k/04
*EVALUED			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

uniber.	0 1 - 11 1 - 6		400.0			~~~~~~~					
	Substitute fo	or form 144	49B/F	10		Complete if Known				4	
	INFORMATI	ON DISC	LOS	URE	_	Application Number	0	9/972,245	Di	-05"	L
	STATEMEN	T BY AP	PLIC	ANT PE	10)	Filing Date	1	0/09/2001	TT	CEN	(EI)
	Date Submitted: May 31, 2002				First Named Inventor	r J	oseph ROBERTS	S et al.			
		•		1 -	MAL	ರ್ಷoup Art Unit	1	645		JUN 072	002
	(use as many s	sheets as	nec	essarx# 0 2	D	Examiner Name	Ų	Inassigned			
Sheet	1		of	1 .70		Attorney Docket Numb	ber 0	78728-0104	TECH (CENTER 18	00/29 00
				T/A	430	Y					, -,

	Cite No.1	U.S. Patent Document			Date of Publication of	Pages, Columns, Lines,
Examiner Initials*		Number	Kind Code² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear
R	A1	5,122,614		ZALIPSKY	06/16/1992	
17	A2	5,324,844		ZALIPSKY	06/28/1994	
	A3	5,612,460		ZALIPSKY	03/18/1997	
115	A4	5,808,096		ZALIPSKY	09/15/1998	

				F	OREIGN PATENT DOCUMEN	TS		
Examiner Initials*	Cite No.1	For Office ³	eign Patent C Number ⁴	Ocument Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Te

		OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T®
K	A 5	ABUCHOWSKI et al.; "Alteration of Immunolological Properties of Bovine Serum Albumin by Covalent Attachment of Polyethylene Glycol"; <i>The Journal of Biological Chemistry</i> ; Vol. 252, No. 11; pp. 3578-3581 (June 10, 1977)	
	A6	FRANCIS et al.; "Polyethylene Glycol Modification: Relevance of Improved Methodology to Tumour Targeting"; Journal of Drug Targeting; Vol. 3; pp. 321-340 (1996)	
	A7	NUCCI et al.; "The therapeutic value of poly(ethylene glycol)-modified proteins"; Advanced Drug Delivery Reviews; Vol. 6, pp. 133-151 (1990)	
1/2)	A8	ZALIPSKY; "Chemistry of polyethylene glycol conjugates with biologically active molecules"; Advanced Drug Delivery Reviews, Vol. 16; pp. 157-182 (1995)	

	$A \cap V$		·
Examiner Signature		Date Considered	8/2/04

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.